medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2013, Number 3

<< Back Next >>

VacciMonitor 2013; 22 (3)

Identification of primary and secondary infection to rubella virus by the detection of IgG avidity in samples of an outbreak occurred in 2004 in Cuba

Ribas MA, Tejero Y, Valcárcel M, Galindo M, Acosta G, García D, Cordero Y

Language: Spanish
References: 19
Page: 4-8
PDF size: 152.59 Kb.


ABSTRACT

Rubella infectious diseases affect children and young adults and when they occur during the first trimester of pregnancy, cause congenital malformations in the newborn. In the National Reference Laboratory (NLR) of measles, rubella and mumps from the Tropical Medicine Institute ¨Pedro Kourí¨, the IgG Avidity Index (AI) detection was carried out to 15 paired serum samples, which corresponded to same number of patients infected with this virus in two Cuban provinces in 2004. The samples were positive to virus- specific IgM antibodies, in addition seroconversion or an increase of › 4 fold of the titers in the sera of the acute and convalescence phase using the hemagglutination inhibition assay (HIA). The AI value showed a primary infection to rubella virus in 13 (86.6%) of the patients studied, and a secondary infection in 2 (13.3%) of them. The IgG avidity antibody detection is a reliable alternative tool for distinguishing between primary and secondary rubella virus infection and for strengthing the diagnosis of this disease in Cuba.


REFERENCES

  1. Hamkar R, Jalilvand S, Abdolbaghi M, Jelyani K, Esteghamati A, Hagh-goo A, et al. Distinguishing between primary infection and reinfection with rubella vaccine virus IgG avidity assay in pregnant women. East Med Health J 2009;15(1):94-103.

  2. Wandinger K, Saschenbrecker S, Steinhagen K, Scheper T, Meyer W, Bartelt U, et al. Diagnosis of recent primary rubella virus infections: significance of glycoprotein-based IgM serology , IgG avidity and immunoblot analysis. J Virol Methods 2011;174:85-93.

  3. Tipples G. Rubella diagnostic issues in Canada. J Infect Dis 2011;2004 (Suppl 2):659-63.

  4. Mubareka S, Richards H, Gray M, Tipples G. Evaluation of Commercial Rubella Immunoglobulin G Avidity Assays. J Clin Microbiol 2007;45(1):231-3.

  5. Shepherd S, Kean J, Hutchinson S, Cameron S, Goldberg D, Carman W, et al. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spot. J Clin Virol 2013;57(1):29-35.

  6. Gershon A, Krugman S. Measles virus. En: Lennette E, Schmidt N. Diagnostic procedure for viral, rickettsial and chlamidial infections. Washington DC: Am Public Health Association; 1979. p. 665-93.

  7. Pannuti C, Morello R, de Moraes J, Pires S, Alfonso A, Correa M, et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin Diag Lab Immunol 2004;11(1):119-22.

  8. Kontio M, Jokinene S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: Implication for MMR vaccine induced protection. J Infect Dis 2012;206(10):1542-8.

  9. De Paschale M, Agrappi C, Manco M, Clerici P. Positive predictive value of anti-HCMV IgM as an index of primary infection. J Virol Meth 2010;168:121-5.

  10. Rota J, Hickman C, Sowers S, Rota P, Mercader S, Bellini W. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: hight risk of infection but low risk of transmission. J Infect Dis 2011;204 (Suppl 1):559-63.

  11. Hickman C, Hyde T, Sowers S, Mercader S, Mc Grew M, Williams N, et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J Infect Dis 2011;204 (Suppl 1): 549-58.

  12. Vicari A, Dietz V, Bellini W, Icenogle J, Castillo C. Interpretation of Measles and Rubella Serology. In: Andrus J, de Quadros C. Recent Advances in Immunization. Washington DC: Pan American Health Organization; 2006. p. 76-86.

  13. Vauloup-Fellous C, Grangeot-Keros L. Humoral Immune Response after Primary Rubella Virus Infection and after Vaccination. Clinical and Vaccine Immunology 2007;14(5):644-7.

  14. Binley JM, Arshad H, Fouts TR, Moore J. An Investigation of the High-Avidity Anibody Response to Glycoprotein 120 of Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses 1997;13(12):1007-15.

  15. Paunio M, Hedmon K, Davidkin I, Valle M, Heinonen O, Leinikki P, et al. Secondary measles vaccine failure identified by mesearument of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect 2000;124(2):263-71.

  16. Narita M, Matsuzono Y, Takekoshi Y, Yamada S, Itakura O, Kubota M, et al. Analysis of Mumps Vaccine Failure by Means of Avidity Testing for Mumps Virus-Specific Immunoglobulin G. Clin Diagn Lab Immunol 1998;5(6):799-803.

  17. Gutiérrez J, Maroto C. Serodiagnóstico de la infección vírica: su interés clínico. Control de Calidad SEIMC 2004:1-8. Disponible en: http://www.seimc.org/control/revi_Sero/ Serovir.htm.

  18. Suresh S, Nor-Masniwati S, Nor-Idhariani M, Wan-Hazabbah W, Zeehaida M, Zunaina E. Serological IgG avidity test for ocular toxoplasmosis. Clin Ophthal 2012;6:147-50.

  19. Mercader S, García P, Bellini W. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination setting. Clinical and Vaccine immunology 2012;19(11):1810-7.




2020     |     www.medigraphic.com